GLP-1 agonists in treatment of obesity
DOI:
https://doi.org/10.12775/JEHS.2023.13.02.033Keywords
obesity, semeglutide, liraglutide, tirzepatideAbstract
Background: Obesity is a major problem nowadays. It has correlation with metabolic and cardiovascular diseases. Due to that it is very important to diagnose and treat obesity properly.
Objective: The purpose of our work is to show effectiveness of GLP1 agonist in treating obesity.
Method: A literature review was conducted in PubMed database using the key words: „Semaglutide obesity” „Tirzepatide obesity” „Liraglutide obesity” „obesity”.
Results: Using particular drug in addition to lifestyle modification appears to be more effective than using placebo with lifestyle modification.
Conclusions: Trials showed effectiveness of GLP1 analogs in treatment of obesity. These drugs might be a future of managing with obesity, but we do not know yet how long lasting is the effect of these drugs. The upcoming years will bring us more trials, but in this moment we can say that they have a lot of potential.
References
Schneider BE, Mun EC. Surgical management of morbid obesity. Diabetes Care 2005;28:475-80
Lotte Bjerre Knudsen , Jesper Lau The Discovery and Development of Liraglutide and Semaglutide
John P.H. Wilding, D.M., Rachel L. Batterham, M.B., B.S., Ph.D., Salvatore Calanna, Ph.D., Melanie Davies, M.D., Luc F. Van Gaal, M.D., Ph.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Barbara M. McGowan, M.D., Ph.D., Julio Rosenstock, M.D., Marie T.D. Tran, M.D., Ph.D., Thomas A. Wadden, Ph.D., Sean Wharton, M.D., Pharm.D., Koutaro Yokote, M.D., Ph.D., Niels Zeuthen, M.Sc., and Robert F. Kushner, M.D. Once-Weekly Semaglutide in Adults with Overweight or ObesityPMID: 33567185 DOI: 10.1056/NEJMoa2032183
Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, M.D., Breno Alves, M.D., Arihiro Kiyosue, M.D., Ph.D., Shuyu Zhang, M.S., Bing Liu, Ph.D., Mathijs C. Bunck, M.D., Ph.D., and Adam Stefanski, M.D., Ph.D. Tirzepatide Once Weekly for the Treatment of Obesity
PMID: 35658024 DOI: 10.1056/NEJMoa2206038
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen , Maria Kabisch, John P H Wilding Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. PMID: 30122305 DOI: 10.1016 S0140-6736(18)31773-2
Aaron S. Kelly, Ph.D., Pernille Auerbach, M.D., Ph.D., Margarita Barrientos-Perez, M.D., Inge Gies, M.D., Ph.D., Paula M. Hale, M.D., Claude Marcus, M.D., Ph.D., Lucy D. Mastrandrea, M.D., Ph.D., Nandana Prabhu, M.Sc., and Silva Arslanian, M.D. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity PMID: 32233338 DOI: 10.1056/NEJMoa1916038
Xavier Pi-Sunyer, M.D., Arne Astrup, M.D., D.M.Sc., Ken Fujioka, M.D., Frank Greenway, M.D., Alfredo Halpern, M.D., Michel Krempf, M.D., Ph.D., David C.W. Lau, M.D., Ph.D., Carel W. le Roux, F.R.C.P., Ph.D., Rafael Violante Ortiz, M.D., Christine Bjørn Jensen, M.D., Ph.D., and John P.H. Wilding, D.M. for the SCALE Obesity and Prediabetes NN8022-1839 Study Group* A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management PMID: 26132939 DOI: 10.1056/NEJMoa1411892
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Władysław Orłowski, Konrad Merkisz, Sylwia Zdun, Klaudia Walczak, Patrycja Walczak, Sylwia Nemeczek, Jakub Grzybowski, Agnieszka Marciniak, Karolina Jaskuła, Natalia Grzywna
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 654
Number of citations: 0
